Joel Lewis Biography and Net Worth

Chief Executive Officer (CEO) and President of Galectin Therapeutics

Joel Lewis is Chief Executive Officer (CEO) and President of Galectin Therapeutics. In this position, Mr. Lewis sets corporate strategy and oversees operations, most importantly Galectin’s global NASH-RX adaptively-designed trial for the prevention of varices in NASH cirrhosis patients using its proprietary galectin-3 inhibiting compound, belapectin (GR-MD-02). Mr. Lewis has served on the Board of Directors for Galectin Therapeutics since 2017. Mr. Lewis is a financial executive with over 25 years of experience, who began his career in public accounting in 1992. From 2007 through 2019, Mr. Lewis acted as the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies). Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition, and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.

What is Joel Lewis' net worth?: The estimated net worth of Joel Lewis is at least $3.62 million as of January 6th, 2026. Mr. Lewis owns 832,592 shares of Galectin Therapeutics stock worth more than $3,621,775 as of July 1st. This net worth evaluation does not reflect any other assets that Mr. Lewis may own. Learn More about Joel Lewis' net worth.
How do I contact Joel Lewis?: The corporate mailing address for Mr. Lewis and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Joel Lewis' contact information.
Has Joel Lewis been buying or selling shares of Galectin Therapeutics?: Joel Lewis has not been actively trading shares of Galectin Therapeutics during the last quarter. Most recently, Joel Lewis sold 37,698 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.58, for a transaction totalling $134,958.84. Following the completion of the sale, the chief executive officer now directly owns 832,592 shares of the company's stock, valued at $2,980,679.36. Learn More on Joel Lewis' trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Jack Callicutt (Chief Financial Officer), Kevin Freeman (Director), Joel Lewis (Chief Executive Officer (CEO) and President), Elissa Schwartz (Director), Harold Shlevin (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 3 times. They purchased a total of 2,000 shares worth more than $6,341.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 944,585 shares worth more than $5,050,478.51. The most recent insider tranaction occured on June, 29th when Director Harold H Shlevin sold 22,268 shares worth more than $112,230.72. Insiders at Galectin Therapeutics own 52.6% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 6/29/2026.

Joel Lewis Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2026	Sell	37,698	$3.58	$134,958.84	832,592
1/5/2026	Sell	27,731	$3.91	$108,428.21	870,290
1/2/2026	Sell	18,571	$4.20	$77,998.20	898,021
12/17/2025	Sell	7,829	$7.06	$55,272.74	832,592
11/5/2025	Sell	200	$6.00	$1,200.00	832,592
11/4/2025	Sell	14,420	$6.07	$87,529.40	832,592
11/3/2025	Sell	1,300	$6.01	$7,813.00	832,592
9/12/2025	Sell	14,000	$6.36	$89,040.00	832,592
12/23/2024	Sell	56,000	$0.89	$49,840.00	897,012
4/24/2024	Buy	1,000	$3.39	$3,390.00	2,000
2/16/2023	Buy	1,000	$1.52	$1,520.00	1,000
6/25/2018	Buy	1,000	$7.06	$7,060.00	51,480

Joel Lewis Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $4.44

$4.28

$4.64

50 Day Range

MA: $2.65

$2.08

$4.97

2 Week Range

Now: $4.44

$2.03

$7.13

Volume

285,628 shs

Average Volume

459,155 shs

Market Capitalization

$292.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47